Carolina Wealth Advisors LLC raised its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 276.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,712 shares of the company's stock after acquiring an additional 2,727 shares during the quarter. Cencora makes up 0.6% of Carolina Wealth Advisors LLC's investment portfolio, making the stock its 28th largest holding. Carolina Wealth Advisors LLC's holdings in Cencora were worth $1,032,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of COR. IFP Advisors Inc grew its stake in Cencora by 105.0% during the 4th quarter. IFP Advisors Inc now owns 1,810 shares of the company's stock valued at $410,000 after acquiring an additional 927 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in Cencora by 0.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 15,051 shares of the company's stock valued at $3,382,000 after acquiring an additional 120 shares in the last quarter. Whipplewood Advisors LLC purchased a new position in Cencora during the 4th quarter valued at about $137,000. New York Life Investment Management LLC grew its stake in Cencora by 1.3% during the 4th quarter. New York Life Investment Management LLC now owns 23,507 shares of the company's stock valued at $5,282,000 after acquiring an additional 303 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. grew its stake in Cencora by 1.7% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 66,500 shares of the company's stock valued at $14,941,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.
Cencora Stock Up 1.1%
COR opened at $299.71 on Friday. The business has a 50 day moving average price of $289.95 and a 200 day moving average price of $264.99. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. The firm has a market cap of $58.09 billion, a P/E ratio of 34.77, a price-to-earnings-growth ratio of 1.47 and a beta of 0.58.
Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion during the quarter, compared to analyst estimates of $75.41 billion. During the same period in the previous year, the company earned $3.80 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. Research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.
Cencora Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.73%. Cencora's dividend payout ratio (DPR) is presently 25.52%.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on COR. Morgan Stanley set a $288.00 target price on Cencora in a research note on Tuesday, April 15th. Citigroup boosted their price target on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Bank of America boosted their price target on Cencora from $270.00 to $285.00 and gave the company a "neutral" rating in a research note on Friday, April 11th. Robert W. Baird boosted their price target on Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Wall Street Zen raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $306.91.
View Our Latest Report on Cencora
Insider Transactions at Cencora
In related news, Chairman Steven H. Collis sold 14,579 shares of the company's stock in a transaction on Tuesday, June 24th. The stock was sold at an average price of $292.62, for a total value of $4,266,106.98. Following the completion of the transaction, the chairman now directly owns 311,913 shares in the company, valued at approximately $91,271,982.06. This represents a 4.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 4,969 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $289.33, for a total value of $1,437,680.77. Following the completion of the transaction, the chief executive officer now owns 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 34,127 shares of company stock worth $9,812,296 over the last three months. 10.80% of the stock is currently owned by insiders.
About Cencora
(
Free Report)
Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Featured Articles
Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cencora, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.
While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
